LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program

Hézode, Christophe; Lédinghen, Victor de; Fontaine, H.; Zoulim, Fabien; Lebray, Pascal; Boyer, Nathalie; Larrey, Dominique; Silvain, Christine; Botta‐Fridlund, Danielle; Leroy, Vincent; Bourlière, Marc; d’Altéroche, Louis; Hubert-Fouchard, I.; Guyader, D.; Rosa, Isabelle; Nguyen‐Khac, Eric; Martino, V. Di; Carrat, Fabrice; Fedchuk, Larysa; Akremi, Raoudha; Bennai, Y.; Bronowicki, J.-P.

doi:10.1016/s0168-8278(15)30159-8

Cited by 55 publications

(74 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there have been several real world data studies which have given similar conclusions. [47][48][49][50][51][52][53] Earlier experience had shown that pegylated interferon (Peg-IFN) and ribavirin (RBV) based treatment regimen failed to achieve desired aims due to poor tolerability and limited efficacy in this unique patient population. Firstly, SVR rates hovered around 25% even when using a low accelerating dose Interferon regimen, 54 and not all patients could be offered treatment.…”

Section: Feasibility and Effectivenessmentioning

confidence: 99%

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Anand

2017

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Section: Feasibility and Effectivenessmentioning

confidence: 99%

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Anand

2017

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

“…Prospective, randomized studies investigating (PEG-)IFN-free treatment which enrolled a significant number of patients with decompensated cirrhosis (Child-Pugh (CP) score > 8; MELD score > 16) are scarce, and safety as well as efficacy data are only available in individual cases for patients with a MELD score > 22 (table 2) [38,39,40,41,42,43,44,45]. In the ALLY-1 study, which enrolled patients with advanced cirrhosis and patients after liver transplantation, sustained virologic response (SVR) was achieved in 11/12 (92%), 30/32 (94%), and 9/16 (56%) patients with CP class A, B, and C cirrhosis, respectively [42].…”

Section: Antiviral Therapy In Hcv-associated Liver Cirrhosis and Hcv mentioning

confidence: 99%

“…The combination of SOF with RBV instead of LDV/SOF with RBV is generally not recommended due to lower efficacy [11]. (Interim) analyses of the prospective phase III study ALLY-1 and compassionate use programs indicate that the use of DCV is safe in patients with advanced cirrhosis [42,44,45]. In contrast, the safety of SMV in patients with decompensated cirrhosis has not been conclusively evaluated [46,47,48,49,50,51].…”

Section: Antiviral Therapy In Hcv-associated Liver Cirrhosis and Hcv mentioning

confidence: 99%

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)

Welker

Zeuzem

2016

Visc Med

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV)- and hepatitis C virus (HCV)-associated liver cirrhosis is a major indication for liver transplantation. This concise review gives an overview about current interferon (IFN)-free treatment options before and after liver transplantation in HBV- or HCV-associated liver disease. Methods: A PubMed database search using the terms hepatitis B, hepatitis C, cirrhosis, and liver transplantation was performed to identify significant clinical studies as well as national and international guidelines. Results: Studies investigating IFN-free treatment in patients with decompensated HBV as well as in HCV-associated cirrhosis are scarce. Hepatic recompensation during antiviral therapy seems more frequent in patients with HBV than in those with HCV-associated cirrhosis. Graft hepatitis B or C is characterized by an accelerated and unfavorable course. Graft infection prophylaxis is safe and efficacious in HBV-related liver transplantation. Eradication of HCV prior to liver transplantation prevents HCV graft infection, and IFN-free treatment of established HCV graft infection is safe and associated with high sustained virologic response rates. Conclusion: Patients with HBV-associated cirrhosis should be treated prior to liver transplantation, and receive a continuing graft infection prophylaxis thereafter. Patients with HCV-associated decompensated cirrhosis may be considered as candidates for antiviral therapy prior to liver transplantation or may be treated subsequently.

show abstract

“…Data from European cohort studies showed that extending the treatment duration to 24 weeks in cirrhotic patients increased SVR12 rate to 88% [28]. Therefore, daclatasvir plus sofosbuvir for 12 weeks in non-cirrhotics or for 24 weeks in cirrhotics (with addition of ribavirin) is recommended.…”

Section: Genotypementioning

confidence: 99%

New treatments for chronic hepatitis C infection

Yapalı¹,

Tözün²

2016

MMJ

View full text Add to dashboard Cite

The goal of HCV treatment is to prevent cirrhosis, hepatocellular carcinoma, liver-related deaths. The development of direct-acting antiviral (DAA) agents which target various steps in HCV lifecycle led to a revolution by providing nearly complete eradication of HCV. The new treatment regimens with high cure rates have changed the standards of care in the regions where patients have access to new treatments. This review addresses the recent updates in management of chronic hepatitis C infection. Keywords: Hepatitis C, New treatments, Direct antiviral agents ÖZHepatit C tedavisinde amaç siroz, siroza bağlı komplikasyonları ve hepatosellüler karsinoma gelişmesi risklerini azaltmak veya tamamiyle ortadan kaldırmaktır. HCV tedavisinde son yıllarda çok önemli gelişmeler kaydedilmiştir. Yeni geliştirilen ve HCV virusunun çoğalmasını engelleyen direkt etkili antiviral ilaçlar ile tama yakın oranlarda virusun eradikasyonu sağlanmaktadır. Bu derlemede yeni geliştirilen bu ilaçlar ile tedaviler detaylı olarak ele alınacaktır.

show abstract

LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program

Cited by 55 publications

References 0 publications

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?

Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)

New treatments for chronic hepatitis C infection

Contact Info

Product

Resources

About